文献速递胸部肿瘤

区域递送间皮素CAR-T联合帕博利珠单抗治疗恶性胸膜疾病的I期试验

A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti-PD-1 Agent Pembrolizumab.
PubMed 文献 · Cancer Discov · 2021-07-15

这项首次人体I期研究评估了胸膜腔内递送自体间皮素靶向CAR-T细胞治疗恶性胸膜疾病的安全性,27例患者(25例MPM)接受0.3M至60M CAR-T细胞/kg,安全可耐受。18例MPM患者后续联合帕博利珠单抗治疗,CAR-T输注后中位总生存23.9个月,1年总生存率83%,8例疾病稳定≥6个月,2例PET完全代谢缓解。

要点

  • 胸膜腔内间皮素CAR-T细胞治疗安全可耐受,外周血可检测CAR-T细胞超过100天。
  • 联合帕博利珠单抗安全,MPM患者中位OS达23.9个月,1年OS率83%。
  • 8例疾病稳定≥6个月,2例PET完全代谢缓解,提示抗肿瘤活性。

核心结论

  • 区域递送间皮素靶向CAR-T细胞后联合帕博利珠单抗可行、安全,并在恶性胸膜疾病中显示抗肿瘤疗效证据。
  • 数据支持在实体瘤中进一步研究CAR-T细胞与PD-1阻断剂的联合免疫治疗。

研究设计与样本

  • 首次人体I期研究,评估区域递送的自体间皮素靶向CAR-T细胞治疗恶性胸膜疾病。
  • 27例患者(25例MPM)接受胸膜腔内CAR-T细胞输注,剂量为0.3M至60M CAR-T细胞/kg。
  • 18例MPM患者后续联合接受帕博利珠单抗治疗。

主要发现

  • 胸膜腔内给予0.3M至60M CAR-T细胞/kg在27例患者中安全且耐受良好。
  • 39%的患者外周血中可检测到CAR-T细胞超过100天。
  • 18例MPM患者联合帕博利珠单抗后,CAR-T输注后中位总生存为23.9个月(1年总生存率83%)。
  • 8例患者疾病稳定持续≥6个月,2例在PET扫描上显示完全代谢缓解。

临床怎么用

  • 对于恶性胸膜疾病(包括MPM),可考虑区域递送间皮素CAR-T细胞联合PD-1阻断剂的治疗策略。
  • 联合方案需在临床试验中进一步评估,当前数据支持在实体瘤中开展后续研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Malignant pleural diseases, comprising metastatic lung and breast cancers and malignant pleural mesothelioma (MPM), are aggressive solid tumors with poor therapeutic response. We developed and conducted a first-in-human, phase I study of regionally delivered, autologous, mesothelin-targeted chimeric antigen receptor (CAR) T-cell therapy. Intrapleural administration of 0.3M to 60M CAR T cells/kg in 27 patients (25 with MPM) was safe and well tolerated. CAR T cells were detected in peripheral blood for >100 days in 39% of patients. Following our demonstration that PD-1 blockade enhances CAR T-cell function in mice, 18 patients with MPM also received pembrolizumab safely. Among those patients, median overall survival from CAR T-cell infusion was 23.9 months (1-year overall survival, 83%). Stable disease was sustained for ≥6 months in 8 patients; 2 exhibited complete metabolic response on PET scan. Combination immunotherapy with CAR T cells and PD-1 blockade agents should be further evaluated in patients with solid tumors. SIGNIFICANCE: Regional delivery of mesothelin-targeted CAR T-cell therapy followed by pembrolizumab administration is feasible, safe, and demonstrates evidence of antitumor efficacy in patients with malignant pleural diseases. Our data support the investigation of combination immunotherapy with CAR T cells and PD-1 blockade agents in solid tumors.See related commentary by Aldea et al., p. 2674.This article is highlighted in the In This Issue feature, p. 2659.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Adusumilli PS, Zauderer MG, Rivière I, et al. A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti-PD-1 Agent Pembrolizumab. Cancer Discov. 2021. PMID: 34266984. doi:10.1158/2159-8290.CD-21-0407

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。